JP2009537507A - アテローム性動脈硬化症に対して保護的な自己抗体を誘導するＩＬ−１α免疫法 - Google Patents
アテローム性動脈硬化症に対して保護的な自己抗体を誘導するＩＬ−１α免疫法 Download PDFInfo
- Publication number
- JP2009537507A JP2009537507A JP2009510567A JP2009510567A JP2009537507A JP 2009537507 A JP2009537507 A JP 2009537507A JP 2009510567 A JP2009510567 A JP 2009510567A JP 2009510567 A JP2009510567 A JP 2009510567A JP 2009537507 A JP2009537507 A JP 2009537507A
- Authority
- JP
- Japan
- Prior art keywords
- atherosclerosis
- mammal
- disease
- mice
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 37
- 230000003053 immunization Effects 0.000 title claims abstract description 15
- 238000002649 immunization Methods 0.000 title abstract description 13
- 230000001681 protective effect Effects 0.000 title description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims abstract description 6
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims abstract description 6
- 230000002093 peripheral effect Effects 0.000 claims abstract description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 5
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 5
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 5
- 241000124008 Mammalia Species 0.000 claims abstract 17
- 241000699670 Mus sp. Species 0.000 claims description 69
- 102000013918 Apolipoproteins E Human genes 0.000 claims description 28
- 108010025628 Apolipoproteins E Proteins 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 24
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 13
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 241000283707 Capra Species 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 241000282326 Felis catus Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229960001005 tuberculin Drugs 0.000 claims description 3
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 241000282887 Suidae Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 210000002966 serum Anatomy 0.000 description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 230000003902 lesion Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 12
- 229940037003 alum Drugs 0.000 description 11
- 210000000709 aorta Anatomy 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 230000003143 atherosclerotic effect Effects 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 101001002629 Mus musculus Interleukin-1 alpha Proteins 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
- 101100404912 Caenorhabditis elegans nob-1 gene Proteins 0.000 description 4
- 239000004380 Cholic acid Substances 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000000923 atherogenic effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 235000019416 cholic acid Nutrition 0.000 description 4
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 4
- 229960002471 cholic acid Drugs 0.000 description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 108700031361 Brachyury Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010048215 Xanthomatosis Diseases 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 101100055876 Mus musculus Apoe gene Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004697 synapse damage Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Compositions Of Oxide Ceramics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80002906P | 2006-05-15 | 2006-05-15 | |
| PCT/IB2007/001264 WO2007132338A2 (en) | 2006-05-15 | 2007-05-15 | IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009537507A true JP2009537507A (ja) | 2009-10-29 |
| JP2009537507A5 JP2009537507A5 (enExample) | 2010-07-01 |
Family
ID=38694276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009510567A Pending JP2009537507A (ja) | 2006-05-15 | 2007-05-15 | アテローム性動脈硬化症に対して保護的な自己抗体を誘導するＩＬ−１α免疫法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090191149A1 (enExample) |
| EP (1) | EP2021033B1 (enExample) |
| JP (1) | JP2009537507A (enExample) |
| CN (1) | CN101448528A (enExample) |
| AT (1) | ATE551365T1 (enExample) |
| AU (1) | AU2007251239B2 (enExample) |
| CA (1) | CA2652274A1 (enExample) |
| ES (1) | ES2384278T3 (enExample) |
| WO (1) | WO2007132338A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015019617A (ja) * | 2013-07-19 | 2015-02-02 | 国立大学法人三重大学 | 閉塞性動脈硬化症モデル動物、るい痩研究用モデル動物、及び全身性アミロイドーシスモデル動物としての非ヒト哺乳動物 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109187944A (zh) * | 2005-08-02 | 2019-01-11 | 埃克斯生物科技公司 | 使用IL-1α自身抗体诊断、治疗和预防血管疾病 |
| US20110008282A1 (en) * | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
| PT2109623E (pt) * | 2006-05-22 | 2012-01-12 | Xbiotech Inc | Tratamento de cancro com anticorpos anti-il-1 |
| CN105467136B (zh) | 2008-05-30 | 2018-02-16 | 埃克斯生物科技公司 | 白细胞介素‑1α抗体及使用方法 |
| WO2010030979A2 (en) | 2008-09-12 | 2010-03-18 | Xbiotech, Inc. | Targeting pathogenic monocytes |
| EP2569640A1 (en) | 2010-05-12 | 2013-03-20 | The University of Birmingham | Biomarker |
| JP6324720B2 (ja) | 2010-06-18 | 2018-05-16 | エックスバイオテク, インコーポレイテッドXbiotech, Inc. | 関節炎治療 |
| KR102748255B1 (ko) | 2010-08-23 | 2024-12-31 | 엑스바이오테크 인코포레이티드 | 종양성 질병들에 대한 치료 |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| JP6204915B2 (ja) | 2011-09-23 | 2017-09-27 | エックスバイオテク, インコーポレイテッドXbiotech, Inc. | 悪液質治療 |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| CN105175503A (zh) * | 2015-09-08 | 2015-12-23 | 苏州普罗达生物科技有限公司 | 因子viii抑制多肽及其应用 |
| CN105175504A (zh) * | 2015-09-08 | 2015-12-23 | 苏州普罗达生物科技有限公司 | 血管性血友病因子抑制多肽及其应用 |
| KR20190117579A (ko) | 2017-02-16 | 2019-10-16 | 엑스바이오테크, 인크. | 화농성 한선염의 치료 |
| US10975146B2 (en) | 2018-06-29 | 2021-04-13 | Cedars-Sinai Medical Center | Interleukin-1 inhibition for combination treatment of pancreatic cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004100987A2 (en) * | 2003-05-06 | 2004-11-25 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat neointimal hyperplasia |
| JP2009503529A (ja) * | 2005-08-02 | 2009-01-29 | エクスバイオテク インコーポレーティッド | ＩＬ−１α自己抗体を用いた血管障害の診断、処置、および予防 |
| JP2009510025A (ja) * | 2005-09-28 | 2009-03-12 | サイトス バイオテクノロジー アーゲー | インターロイキン−１コンジュゲート及びその使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9802402D0 (sv) * | 1998-07-03 | 1998-07-03 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
| US6555579B2 (en) * | 1998-08-13 | 2003-04-29 | The Wistar Institute | Methods for reducing atherosclerotic plaques |
| US20030040617A9 (en) * | 1999-03-12 | 2003-02-27 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| US20030232054A1 (en) * | 2000-01-25 | 2003-12-18 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| US20030026806A1 (en) * | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| CN105467136B (zh) * | 2008-05-30 | 2018-02-16 | 埃克斯生物科技公司 | 白细胞介素‑1α抗体及使用方法 |
| WO2010030979A2 (en) * | 2008-09-12 | 2010-03-18 | Xbiotech, Inc. | Targeting pathogenic monocytes |
-
2007
- 2007-05-15 AU AU2007251239A patent/AU2007251239B2/en active Active
- 2007-05-15 US US12/300,712 patent/US20090191149A1/en not_active Abandoned
- 2007-05-15 ES ES07734572T patent/ES2384278T3/es active Active
- 2007-05-15 CA CA002652274A patent/CA2652274A1/en not_active Abandoned
- 2007-05-15 CN CNA2007800186140A patent/CN101448528A/zh active Pending
- 2007-05-15 JP JP2009510567A patent/JP2009537507A/ja active Pending
- 2007-05-15 EP EP07734572A patent/EP2021033B1/en active Active
- 2007-05-15 WO PCT/IB2007/001264 patent/WO2007132338A2/en not_active Ceased
- 2007-05-15 AT AT07734572T patent/ATE551365T1/de active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004100987A2 (en) * | 2003-05-06 | 2004-11-25 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat neointimal hyperplasia |
| JP2009503529A (ja) * | 2005-08-02 | 2009-01-29 | エクスバイオテク インコーポレーティッド | ＩＬ−１α自己抗体を用いた血管障害の診断、処置、および予防 |
| JP2009510025A (ja) * | 2005-09-28 | 2009-03-12 | サイトス バイオテクノロジー アーゲー | インターロイキン−１コンジュゲート及びその使用 |
Non-Patent Citations (4)
| Title |
|---|
| JPN5008011508; Ｄａｒｄｉｋ Ａ， ｅｔ ａｌ．: 'Ｓｈｅａｒ ｓｔｒｅｓｓ-ｓｔｉｍｕｌａｔｅｄ ｅｎｄｏｔｈｅｌｉａｌ ｃｅｌｌｓ ｉｎｄｕｃｅ ｓｍｏｏｔｈ ｍｕｓｃｌｅ ｃｅｌｌ ｃｈｅｍｏｔａｘｉｓ ｖｉａ ｐｌａｔｅｌｅｔ-ｄｅｒｉｖｅｄ' Ｊｏｕｒｎａｌ ｏｆ Ｖａｓｃｕｌａｒ Ｓｕｒｇｅｒｙ Ｖｏｌ． ４１， Ｎｏ． ２, 200502, ｐ． ３２１-３３１ * |
| JPN5008011515; Ｇａｒｒｏｎｅ Ｐ， ｅｔ ａｌ．: 'Ｇｅｎｅｒａｔｉｏｎ ａｎｄ ｃｈａｒａｃｔｅｒｉｚａｔｉｏｎ ｏｆ ａ ｈｕｍａｎ ｍｏｎｏｃｌｏｎａｌ ａｕｔｏａｎｔｉｂｏｄｙ ｔｈａｔ ａｃｔｓ ａｓ ａ ｈｉｇｈ ａｆｆｉｎｉｔｙ ｉｎｔｅ' Ｍｏｌｅｃｕｌａｒ Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ． ３３， Ｎｏ． ７-８, 199605, ｐ． ６４９-６５８ * |
| JPN6012002566; Ｊｏｕｒｎａｌ ｏｆ Ｉｍｍｕｎｏｌｏｇｉｃａｌ Ｍｅｔｈｏｄｓ Ｖｏｌ．２３６，Ｎｏ．１-２, 2000, ｐ１-８ * |
| JPN6012028876; Ｃａｒｄｉｏｖａｓｃｕｌａｒ Ｒｅｓｅａｒｃｈ Ｖｏｌ．６６, 2005, ｐ．５８３-５９３ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015019617A (ja) * | 2013-07-19 | 2015-02-02 | 国立大学法人三重大学 | 閉塞性動脈硬化症モデル動物、るい痩研究用モデル動物、及び全身性アミロイドーシスモデル動物としての非ヒト哺乳動物 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2384278T3 (es) | 2012-07-03 |
| WO2007132338A3 (en) | 2008-06-12 |
| WO2007132338A2 (en) | 2007-11-22 |
| CA2652274A1 (en) | 2007-11-22 |
| CN101448528A (zh) | 2009-06-03 |
| EP2021033A2 (en) | 2009-02-11 |
| EP2021033A4 (en) | 2010-02-24 |
| ATE551365T1 (de) | 2012-04-15 |
| US20090191149A1 (en) | 2009-07-30 |
| EP2021033B1 (en) | 2012-03-28 |
| AU2007251239A1 (en) | 2007-11-22 |
| AU2007251239B2 (en) | 2013-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009537507A (ja) | アテローム性動脈硬化症に対して保護的な自己抗体を誘導するＩＬ−１α免疫法 | |
| US20120114598A1 (en) | IL-1alpha immunization induces autoantibodies protective against atherosclerosis | |
| Klinman et al. | DNA vaccines: safety and efficacy issues | |
| Chitnis et al. | Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis | |
| Regan et al. | Characterization of cytokines associated with Th17 cells in the eyes of horses with recurrent uveitis | |
| Bates et al. | Mucosal adjuvant activity of flagellin in aged mice | |
| US20150313977A1 (en) | Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom | |
| Szabo et al. | Maternal P2X7 receptor inhibition prevents autism-like phenotype in male mouse offspring through the NLRP3-IL-1β pathway | |
| JP6955324B2 (ja) | 医薬化合物を評価するための新規動物モデル | |
| US20140227304A1 (en) | Vaccines for preventing and treating alzheimer's disease | |
| Thelemann et al. | Absence of nonhematopoietic MHC class II expression protects mice from experimental autoimmune myocarditis | |
| Irony-Tur-Sinai et al. | Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein | |
| Constantinescu et al. | Modulation of susceptibility and resistance to an autoimmune model of multiple sclerosis in prototypically susceptible and resistant strains by neutralization of interleukin-12 and interleukin-4, respectively | |
| Ishikawa et al. | Commercial bovine proteoglycan is highly arthritogenic and can be used as an alternative antigen source for PGIA model | |
| Austin et al. | Short-term β-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP+ PS1 mice. | |
| Babai et al. | Depletion of peritoneal CD5+ B cells has no effect on the course of Leishmania major infection in susceptible and resistant mice | |
| Wildbaum et al. | Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis | |
| JPS6121A (ja) | ワクチンおよびその製造法 | |
| Kim et al. | Protective effect of the DNA vaccine encoding the major house dust mite allergens on allergic inflammation in the murine model of house dust mite allergy | |
| JP5068505B2 (ja) | 乳アレルギーモデル動物 | |
| Alderuccio et al. | Organ-specific autoimmunity in granulocyte macrophage-colony stimulating factor (GM-CSF) deficient mice | |
| Bakela et al. | Rescue of autoimmune hepatitis by soluble MHC class II molecules in an altered concanavalin A‐induced experimental model | |
| Bungiro Jr et al. | Interleukin-12 as an adjuvant for an antischistosome vaccine consisting of adult worm antigens: protection of rats from cercarial challenge | |
| JP7411970B2 (ja) | 乳汁中のＩｇＡ抗体含有量の増加剤 | |
| JP2010509321A (ja) | 種々の炎症状態の治療用の新規な組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100513 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110413 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120905 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130508 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130806 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130813 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140108 |